RECRUITING

Staphylococcus Aureus Network Adaptive Platform Trial

Conditions

Staphylococcus Aureus Bacteremia Methicillin-resistant Staphylococcus aureus (MRSA)Methicillin-susceptible Staphylococcus aureus (MSSA)Penicillin-susceptible Staphylococcus aureus (PSSA)Staphylococcus aureus S. aureus Staph Aureus Bacteremia (SAB)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).

Official Title

Staphylococcus Aureus Network Adaptive Platform Trial

Quick Facts

Study Start:2022-02-16

Study Completion:2028-12-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05137119

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Staphylococcus aureus complex grown from ≥1 blood culture 2. Admitted to a participating hospital at the time of eligibility assessment	1. Time of anticipated platform entry is greater than 72 hours post collection of the index blood culture. Where the time of culture collection is not recorded, the time of laboratory registration of the sample will be used as an alternative 2. Polymicrobial bacteraemia, defined as more than one organism (at species level) in the index blood cultures OR in any subsequent blood culture reported between the collection of the index blood culture and platform eligibility assessment, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician. 3. Known previous participation in the randomised SNAP platform 4. Known positive blood culture for S. aureus (of the same silo: PSSA, MSSA or MRSA) between 72 hours and 180 days prior to the time of eligibility assessment 5. Treating team deems enrolment in the study is not in the best interest of the patient 6. Treating team believes that death is imminent and inevitable 7. Patient is for end-of-life care and antibiotic treatment is considered not appropriate 8. Patient \<18 years of age and paediatric recruitment not approved at recruiting site 9. Patient has died since the collection of the index blood culture

Inclusion Criteria

Exclusion Criteria

1. Staphylococcus aureus complex grown from ≥1 blood culture
2. Admitted to a participating hospital at the time of eligibility assessment

1. Time of anticipated platform entry is greater than 72 hours post collection of the index blood culture. Where the time of culture collection is not recorded, the time of laboratory registration of the sample will be used as an alternative
2. Polymicrobial bacteraemia, defined as more than one organism (at species level) in the index blood cultures OR in any subsequent blood culture reported between the collection of the index blood culture and platform eligibility assessment, excluding those organisms judged to be contaminants by either the microbiology laboratory or treating clinician.
3. Known previous participation in the randomised SNAP platform
4. Known positive blood culture for S. aureus (of the same silo: PSSA, MSSA or MRSA) between 72 hours and 180 days prior to the time of eligibility assessment
5. Treating team deems enrolment in the study is not in the best interest of the patient
6. Treating team believes that death is imminent and inevitable
7. Patient is for end-of-life care and antibiotic treatment is considered not appropriate
8. Patient \<18 years of age and paediatric recruitment not approved at recruiting site
9. Patient has died since the collection of the index blood culture

Contacts and Locations

Study Contact

Lauren Barina

CONTACT

+61 (03) 8344 1623

lauren.barina@unimelb.edu.au

Susan Goulding

CONTACT

+61 (03) 8344 7799

susan.goulding@unimelb.edu.au

Principal Investigator

Prof Steven Tong

STUDY_CHAIR

University of Melbourne / Melbourne Health

Prof Joshua Davies

STUDY_CHAIR

Menzies School of Research / Hunter New England Medical Centre

Study Locations (Sites)

Houston Methodist Research Institute

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: University of Melbourne

Prof Steven Tong, STUDY_CHAIR, University of Melbourne / Melbourne Health
Prof Joshua Davies, STUDY_CHAIR, Menzies School of Research / Hunter New England Medical Centre

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-02-16

Study Completion Date2028-12-01

Study Record Updates

Study Start Date2022-02-16

Study Completion Date2028-12-01

Terms related to this study

Keywords Provided by Researchers

Methicillin-resistant Staphylococcus aureus (MRSA)
Methicillin-susceptible Staphylococcus aureus (MSSA)
Penicillin-susceptible Staphylococcus aureus (PSSA)
Staphylococcus aureus
S. aureus
Staph Aureus Bacteremia (SAB)

Additional Relevant MeSH Terms

Staphylococcus Aureus Bacteremia